Neural Therapeutics’ Hanf.com Stake Delivers 58% Revenue Surge and Positive Operating Income

The latest update is out from Neural Therapeutics Inc. ( (TSE:NURL) ).

Neural Therapeutics Inc. reported that its portfolio company CWE European Holdings, operating as Hanf.com, achieved approximately 58% year‑over‑year revenue growth in fiscal 2025 to about CAD $11.2 million, driven by an expansion into lower‑margin wholesale channels across Germany. While this shift reduced gross margins to roughly 35%, CWE improved operating leverage, expects positive normalized operating income of about CAD $280,000, and views its broader wholesale and retail footprint, exclusive product lines, and scaling strategy as positioning the CBD retailer for continued profitable growth.

Neural also disclosed that it has postponed and will reschedule its shareholders’ meeting to finalize disclosure materials related to matters that include the potential exercise of its Series B option to acquire the remaining 69.25% of CWE, all subject to regulatory approvals. The strong performance of Hanf.com underscores the strategic value of Neural’s minority stake and highlights the company’s growing indirect exposure to Europe’s wellness‑oriented CBD market as it considers whether to increase its ownership position.

More about Neural Therapeutics Inc.

Neural Therapeutics Inc. is an ethnobotanical drug discovery company developing therapeutic drugs for mental health conditions related to substance use disorders, including alcohol and opioid dependence. The company’s strategy centers on sub‑hallucinogenic doses of mescaline and it holds a 30.75% stake in CWE European Holdings Inc., which operates Hanf.com, a leading German CBD retailer with growing European exposure.

Average Trading Volume: 249,523

Technical Sentiment Signal: Strong Sell

Current Market Cap: C$2.53M

See more insights into NURL stock on TipRanks’ Stock Analysis page.